Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences
Prof. Sadhana Sathaye is an eminent research scientist working in the field of pharmacology with an academic experience of 24 years. The overreaching fields of her research encompass various neurological and neurodegenerative disorders like epilepsy, Parkinson’s and Alzheimer’s disease along with diabetes mellitus and related complications. Her research group works with a clear vision of establishing novel therapeutic interventions as well as neutraceutical supplements by exploring herbs and modern medicinal drugs. She has over 63 national and international publications to her credentials and has been a renowned speaker in several esteemed national and international conferences. Her horizon is not limited to academia but expands to industry wherein she extends her services as a consultant to the pharmaceutical industry in India.
Statement of the Problem: Parkinson's disease (PD) is a second most common, slowly progressive, neurodegenerative disorder. The motor and non-motor neuropsychiatric symptoms namely dementia, depression, anxiety, apathy and psychosis affect patient’s quality and quantity of life. This imposes enormous burden on patient’s family and a serious economic drain on the society. Genetic susceptibility, stressful lifestyle and environmental factors contribute in the PD pathophysiology. These factors increase oxidative stress related damage, triggering the inflammatory cascade and ultimately neuronal apoptosis. This leads to progression of neuronal degeneration and appearance of PD symptoms. Thus, development of therapeutic strategies for symptomatic relief along with disease modifying effects becomes the urgent clinical need. Multitude of evidences suggests that nutritional supplements and indigenous phytoconstituents prevent/cure most life-threatening diseases and exhibit several therapeutic benefits such as neuroprotection, antioxidant potential, neurogenesis, enhancement of synaptic plasticity etc. Thus, we aim to investigate the effect of polyphenols such as apigenin and luteolin which are commonly present in many plants for their therapeutic potential in PD. Methodology & Theoretical Orientation: We evaluated the therapeutic roles of the apigenin and luteolin by treating MPTP induced mice for 21 days. The activity was studied with the help of various behavioral and biochemical parameters. The biochemical parameters included the estimation of oxidative stress, inflammation, neurotrophic factors and neurogenesis. Findings: Our results demonstrated that apigenin and luteolin treatment improved the locomotor and motor activities in MPTP treated mice. Both significantly enhanced the endogenous antioxidant enzyme activity and curbed inflammation in the neuronal cells. The reduction in TH-positive cells caused by MPTP treatment was protected by Apigenin and luteolin. Significant elevation in neurotrophic factor (BDNF) was also observed. Additionally, both the polyphenols promoted neurogenesis and were found to enhance spatial memory formation in animals. Conclusion & Significance: Our study endorses neuroprotective, neurotrophic and neurogenesis potential of apigenin and luteolin at preclinical stage. They can be prospective candidates to slow/halt the progression of PD and improve the overall quality of life of PD patient. Findings of the present study suggest that healthy and balanced diet rich with nutritional constituents can improve general well-being and quality of life.